SCHEMBL79480

SCHEMBL79480

Cc1ccc(C#CCO)cc1Cl

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MELK Q14680 1/20 0.42
CYP3A4 P08684 1/20 0.39
EGFR P00533 1/20 0.37
MMP2 P08253 1/20 0.37
MMP12 P39900 1/20 0.37
KCNJ5 P48544 1/20 0.36
KCNJ3 P48549 1/20 0.36
ALDH1A1 P00352 2/20 0.36
GAA P10253 2/20 0.35
HRH3 Q9Y5N1 1/20 0.35
PGK1 P00558 1/20 0.35
GABRP O00591 1/20 0.35
GABRD O14764 1/20 0.35
GABRA1 P14867 1/20 0.35
GABRB1 P18505 1/20 0.35
GABRG2 P18507 1/20 0.35
GABRB3 P28472 1/20 0.35
GABRA5 P31644 1/20 0.35
GABRA3 P34903 1/20 0.35
GABRA2 P47869 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL81541 0.85 MELK (0.42) MELKEGFRMMP2MMP12KCNJ5
SCHEMBL23843465 0.83 CYP3A4 (0.41) CYP3A4ALDH1A1GAAPGK1GABRP
SCHEMBL81322 0.82 MELK (0.46) MELKMMP2MMP12ALDH1A1HRH3
SCHEMBL78739 0.82 PYGL (0.47) MELKCYP3A4EGFRMMP2MMP12
SCHEMBL12197995 0.79 CYP3A4 (0.37) CYP3A4GAASLC6A4
SCHEMBL80540 0.78 EGFR (0.54) MELKEGFRMMP2MMP12KCNJ5
SCHEMBL17733479 0.76 MELK (0.41) MELKMMP2MMP12ALDH1A1GABRP
SCHEMBL8772370 0.76 CYP3A4 (0.50) CYP3A4ALDH1A1GAAHPGDMAPT
SCHEMBL11216099 0.76 HPGD (0.40) MELKCYP3A4EGFRMMP2MMP12
SCHEMBL3730099 0.74 MELK (0.42) MELKEGFRMMP2MMP12ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2168944-B1 AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2016-05-11 EP disclosed
US-8129361-B2 Amine compound and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-03-06 US disclosed
US-8129361-B2 Amine compound and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-03-06 US disclosed
US-20100179216-A1 AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-07-15 US disclosed
US-20100179216-A1 AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-07-15 US disclosed
EP-2168944-A1 AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF Mitsubishi Tanabe Pharma Corporation (JP) 2010-03-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100179216-A1 AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF HLA-B, HLA-A, HLA-C MELK 783/4885CYP3A4 123/4885EGFR 3860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.